Firebrick Pharma Limited

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

N/A

Website

firebrickpharma.com

Country

Australia

Exchange

ASX

Firebrick Pharma provides the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and globally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Key Stats

52-Week Range

A$0.03A$0.09

Beta0.85

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.01

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.